Wockhardt

Wockhardt now intends to file a new drug application (NDA) with the USFDA and seek marketing authorisation application with European Medicines Agency (EMA)

Shares of Wockhardt were in high demand on Monday after the company said that its drug Zaynich has achieved over 97 per cent clinical efficacy in treating critically ill patients

The Indian drug regulator, Central Drugs Standard Control Organization (CDSCO) has approved Miqnaf (nafithromycin) as a new treatment for the Community-Acquired Bacterial Pneumonia (CABP) in Adults

Wockhardt stock gained 10% to touch Rs 1,536.40; it has outperformed the market by zooming 262% thus far in calendar year 2024, as compared to the 13% rise in the BSE Sensex

Wockhardt's nafithromycin is India's first FDA-approved antimicrobial that is seen as an alternative to existing antibiotics like azithromycin, which is facing increasing resistance in humans

Drug firm Wockhardt on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, 2024. The company has reported a net loss of Rs 73 crore in July-September quarter of last fiscal. Revenue from operations stood at Rs 809 crore for the second quarter as compared with Rs 753 crore in the year-ago period, the Mumbai-based drug maker said in a regulatory filing. Shares of the company were trading 0.63 per cent up at Rs 1,189 apiece on BSE.

Wockhardt shares surged 5% to Rs 1,212.55, its highest level since February 2016 and has zoomed 157% thus far in the calendar year 2024.

Wockhardt is also developing additional insulin analogs and GLP-1 agonists to provide advanced diabetes care solutions

A positive response from CDSCO will give a push to the company efforts to gain the Drugs Controller General of India's (DCGI) final approval for Miqnaf

Drug firm Wockhardt on Friday said the national drug regulator has accorded a favourable recommendation for its novel antibiotic developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has provided a favourable recommendation for Miqnaf (nafithromycin), the drug firm said in a statement. The SEC recommendation is based on CDSCO's comprehensive review of the product dossier consisting of non-clinical, US/EU Phase 1, Global Phase 2 and India Phase 3 clinical studies conducted over the last 15 years, it added. A positive opinion from the SEC of CDSCO would pave the way for gaining DCGI's final approval for Miqnaf, the company stated. Miqnaf is the once-a-day 3-days-only treatment for CABP patients, including those caused by multi-drug resistant (MDR) bugs. CABP is the most common infection, leading to hospitalisation and death. Globally, 2.4 million annual dea

WCK 6777 is a once-a-day, β-lactam enhancer used for outpatient parenteral antimicrobial therapy

After ICICI and Wockhardt; M&M, Dr.Reddy's and Pidilite are the latest company names to be dragged in the Congress versus Sebi chief controversy. Here's a technical outlook on these stocks.

Drug firm Wockhardt has denied allegations regarding payment of rent by Carol Info Services and its connection with certain orders passed by SEBI in relation to the company. "In this regard, we categorically deny these allegations and state that these allegations are completely baseless and misleading," Wockhardt said in a regulatory filing late Friday. It said the company has acted and continues to act in compliance with all applicable laws. On Friday, the Congress' media and publicity department head, Pawan Khera said that between 2018 and 2024, Madhabi Buch - as a whole-time member and later chairperson of Securities and Exchange Board of India (SEBI) - had been receiving rental income amounting to Rs 2.16 crore from Carol Info Services, a company affiliated to Wockhardt. Mumbai-based Wockhardt was being investigated by SEBI for various cases, including that of insider trading during 2023, he said at a press conference at the AICC headquarters in Delhi.

This came after the Congress party accused Securities and Exchange Board of India (Sebi) chairperson Madhabi Puri Buch of a conflict of interest involving the pharmaceutical firm Wockhardt

Global launch in FY26 after multinational clinical trial ends

Stocks to watch on May 29: Wockhardt reported its Q4 earnings, disclosing a net loss of Rs 177 crore compared to a loss of Rs 237 crore YoY

Drug firm Wockhardt on Tuesday reported a consolidated net loss of Rs 177 crore for the fourth quarter ended March 31, 2024. The company had reported a net loss of Rs 237 crore in the January-March quarter of 2022-23. Revenue from operations stood at Rs 700 crore for the period under review as compared with Rs 678 crore in the same period of FY23, the Mumbai-based drugmaker said in a regulatory filing. For the year ended March 31, 2024, the company reported a net loss of Rs 472 crore against a net loss of Rs 621 crore in 2022-23 fiscal. Revenue from operations increased to Rs 2,798 crore in FY24 compared with Rs 2,651 crore in FY23. The company said its board approved the re-appointment of Habil Khorakiwala as Executive Chairman for a further term of five years with effect from March 1, 2025, to February 28, 2030. Shares of the company on Tuesday ended 0.49 per cent down at Rs 557.95 apiece on the BSE.

The hospital group also claims that the ERP program improves the survival rate of the patients by approximately 2-3 per cent while enhancing patient outcomes through advanced techniques

Pharmaceuticals firm Wockhardt Ltd on Wednesday reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023. The company had incurred a loss of Rs 102 crore in the third quarter last fiscal, Wockhardt Ltd said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in the year-ago period, the company said. Total expenses were lower at Rs 796 crore as against Rs 803 crore in the same period last fiscal.

Wockhardt hit a fresh 52-week high of Rs 334.50, surging 19% on the BSE in Thursday's intra-day trade on the back of heavy volumes